My HPRA: Register

The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Lemsip Multirelief capsules Paracetamol 500mg Phenylephrine hydrochloride 6.1mg Guaifenesin 100mg



Reckitt Benckiser Ireland LtdPA0979/053/001

Main Information

Trade NameLemsip Multirelief capsules Paracetamol 500mg Phenylephrine hydrochloride 6.1mg Guaifenesin 100mg
Active SubstancesParacetamol
Phenylephrine hydrochloride
Guaifenesin
Dosage FormCapsule, hard
Licence HolderReckitt Benckiser Ireland Ltd
Licence NumberPA0979/053/001

Group Information

ATC CodeN02BE Anilides
N02BE51 paracetamol, combinations excl. psycholeptics

Status

License statusAuthorised
Licence Issued06/08/2010
Legal statusProduct not subject to medical prescription
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to the general public
Conditions of LicenceParacetamol Retail sale through pharmacies only in blister packs containing not more than 24 unit dosage forms. Not more than two such packs should be supplied in the course of any one retail transaction unless a valid prescription exists. Packs containing more than 24 unit dosage forms may be supplied to pharmacies for the use by pharmacists provided the label states that they are for dispensing purposes only. Packs containing more than 50 unit dosage forms are prescription only. Promotion to the public subject to the following restrictions for phenylephrine base: maximum dose 12.2mg, maximum daily dose 48.8mg. Paracetamol Promotion to the general public for packs containing not more than 24 unit dosage forms Promotion to healthcare professionals only for packs containing more than 24 unit dosage forms.
Marketing StatusMarketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportPDF Version
« Back
Follow medicine

Print